Support Care Cancer (2016) 24:457–458
DOI 10.1007/s00520-015-2985-1

ERRATUM

Erratum to: Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer

Alison T. Stopeck[1] · Karim Fizazi[2] · Jean-Jacques Body[3] · Janet E. Brown[4,5] · Michael Carducci[6] · Ingo Diel[7] · Yasuhiro Fujiwara[8] · Miguel Martín[9] · Alexander Paterson[10] · Katia Tonkin[11] · Neal Shore[12] · Paul Sieber[13] · Frank Kueppers[14] · Lawrence Karsh[15] · Denise Yardley[16] · Huei Wang[17] · Tapan Maniar[17] · Jorge Arellano[17] · Ada Braun[17]

Published online: 19 October 2015

Erratum to: **Support Care Cancer (2015)**
DOI 10.1007/s00520-015-2904-5

Table 3. The adverse event of 'Anemia' in the Denosumab/ Denosumab column under the Breast Cancer Study is 53 (16.7 %).

The online version of the original article can be found at http://dx.doi.org/10.1007/s00520-015-2904-5.

✉ Alison T. Stopeck
Alison.Stopeck@stonybrookmedicine.edu

[1] University of Arizona Cancer Center, Tucson, AZ, USA

[2] Institut Gustave Roussy, University of Paris Sud, Villejuif, France

[3] Centre Hospitalier Universitaire Brugmann, Université Libre de Bruxelles, Brussels, Belgium

[4] Cancer Research UK Experimental Cancer Medicine Centres, St James's University Hospital, Leeds, UK

[5] Weston Park Hospital, University of Sheffield, Sheffield, UK

[6] Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA

[7] Center for Comprehensive Gynecology Clinic, Mannheim, Germany

[8] National Cancer Center Hospital, Tokyo, Japan

[9] Instituto de Investigación Sanitaria General Gregorio Marañón, Universidad Complutense, Madrid, Spain

[10] Tom Baker Cancer Centre, Calgary, AB, Canada

[11] Cross Cancer Institute, Edmonton, AB, Canada

[12] Carolina Urologic Research Center, Myrtle Beach, SC, USA

[13] Lancaster Urology, Lancaster, PA, USA

[14] Urology Associates, Christchurch, New Zealand

[15] The Urology Center of Colorado, Denver, CO, USA

[16] Sarah Cannon Research Institute, Nashville, TN, USA

[17] Amgen Inc., Thousand Oaks, CA, USA

Table 3 Adverse events during the open-label treatment phase

Event, *n* (%)	Breast cancer study		Prostate cancer study	
	Denosumab/Denosumab (*N*=318)[a]	Zoledronic acid/Denosumab (*N*=334)[a]	Denosumab/Denosumab (*N*=147)[a]	Zoledronic acid/Denosumab (*N*=118)[a]
All adverse events	283 (89.0)	303 (90.7)	138 (93.9)	105 (89.0)
Serious adverse events	126 (39.6)	133 (39.8)	78 (53.1)	63 (53.4)
Most common adverse events				
Nausea	72 (22.6)	77 (23.1)	20 (13.6)	16 (13.6)
Anemia	53 (16.7)	50 (15.0)	34 (23.1)	26 (22.0)
Fatigue	70 (22.0)	74 (22.2)	23 (15.6)	15 (12.7)
Back pain	66 (20.8)	56 (16.8)	29 (19.7)	19 (16.1)
Asthenia	40 (12.6)	48 (14.4)	29 (19.7)	11 (9.3)
Arthralgia	57 (17.9)	61 (18.3)	25 (17.0)	17 (14.4)
Adverse events of infection[b]	135 (42.5)	135 (40.4)	58 (39.5)	33 (28.0)
Osteonecrosis of the jaw (ONJ)[c,d]	20 (6.3)	18 (5.4)	12 (8.2)	7 (5.9)
CTCAE, v 3 grade 3	2 (0.6)	6 (1.8)	3 (2.0)	1 (0.8)
CTCAE, v 3 grade 4	0 (0.0)	1 (0.3)	0 (0.0)	1 (0.8)
Adverse events of new primary malignancy[e]	2 (0.6)[f]	1 (0.3)[g]	1 (0.7)[h]	0 (0.0)
Adverse events of hypocalcemia[i]	12 (3.8)	9 (2.7)	8 (5.4)	5 (4.2)
Serious	3 (0.9)	0 (0.0)	1 (0.7)	1 (0.8)

CTCAE common terminology criteria for adverse events; version 3

[a] Number of patients who received at least one dose of open-label denosumab

[b] System organ class: Infections and Infestations, Medical Dictionary for Regulatory Activities version 14.0 (breast cancer study), 14.1 (prostate cancer study)

[c] Positively adjudicated by blinded committee of experts. There were no grade 5 ONJ events

[d] Rates not adjusted for patient-years of investigational product exposure and patient follow-up

[e] No events were considered by the investigator to be related to denosumab treatment

[f] Renal cell cancer, squamous cell carcinoma of the skin

[g] Germ cell cancer

[h] Bladder cancer

[i] Includes the preferred terms hypocalcemia and blood calcium decreased